Pliant Therapeutics Inc expected to post a loss of 72 cents a share - Earnings Preview

Pliant Therapeutics

02/05/2025 12:33

Pliant Therapeutics Inc PLRX.OQ PLRX.O is expected to show no change in quarterly revenue when it reports  results on May 5 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Pliant Therapeutics Inc is for a loss of 72 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 11 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 0.6% in the last three months. ​

Wall Street's median 12-month price target for Pliant Therapeutics Inc is $3.00​, above​ its last closing price of $1.62. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.98
-0.98
-0.82
Beat
16.6
Sep. 30 2024
-0.96
-0.97
-0.95
Beat
2
Jun. 30 2024
-0.83
-0.85
-0.92
Missed
-8.4​
Mar. 31 2024
-0.75
-0.77
-0.78
Missed
-1.1
​​Dec. 31 2023
-0.77
-0.81
-0.69
Beat
15.2
Sep. 30 2023
-0.76
-0.77
-0.70
Beat
9.7​
Jun. 30 2023
-0.72
-0.71
-0.70
Beat
1.9
Mar. 31 2023
-0.65
-0.67
-0.67
Met
-0.2

This summary was machine generated May 2 at 11:33 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)